These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19139199)

  • 1. Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3.
    Toure-Balde A; Perlaza BL; Sauzet JP; Ndiaye M; Aribot G; Tall A; Sokhna C; Rogier C; Corradin G; Roussilhon C; Druilhe P
    Infect Immun; 2009 Mar; 77(3):1189-96. PubMed ID: 19139199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice.
    Perlaza BL; Sauzet JP; Balde AT; Brahimi K; Tall A; Corradin G; Druilhe P
    Eur J Immunol; 2001 Jul; 31(7):2200-9. PubMed ID: 11449374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.
    Calvo-Calle JM; Oliveira GA; Watta CO; Soverow J; Parra-Lopez C; Nardin EH
    Infect Immun; 2006 Dec; 74(12):6929-39. PubMed ID: 17030584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malaria vaccine based on self-assembling protein nanoparticles.
    Burkhard P; Lanar DE
    Expert Rev Vaccines; 2015; 14(12):1525-7. PubMed ID: 26468608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity.
    Theisen M; Dodoo D; Toure-Balde A; Soe S; Corradin G; Koram KK; Kurtzhals JA; Hviid L; Theander T; Akanmori B; Ndiaye M; Druilhe P
    Infect Immun; 2001 Sep; 69(9):5223-9. PubMed ID: 11500389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmodium falciparum liver-stage antigen-1 peptide-specific interferon-gamma responses are not suppressed during uncomplicated malaria in African children.
    Luty AJ; Bongartz M; Rezbach P; Faucher JF; Hollingdale MR; Kremsner PG
    Eur Cytokine Netw; 2001; 12(4):647-53. PubMed ID: 11781192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors.
    Lopez JA; Roggero MA; Duombo O; Gonzalez JM; Tolle R; Koita O; Arevalo-Herrera M; Herrera S; Corradin G
    Am J Trop Med Hyg; 1996 Oct; 55(4):424-9. PubMed ID: 8916800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic declines in seropositivity as determined with crude extracts of Plasmodium falciparum schizonts between 2000 and 2010 in Dielmo and Ndiop, Senegal.
    Diop F; Richard V; Diouf B; Sokhna C; Diagne N; Trape JF; Faye MM; Tall A; Diop G; Balde AT
    Malar J; 2014 Mar; 13():83. PubMed ID: 24602390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody responses to Plasmodium falciparum sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas.
    Ferreira-da-Cruz MF; Deslandes DC; Oliveira-Ferreira J; Montenegro-James S; Tartar A; Druilhe P; Daniel-Ribeiro CT
    Parasite; 1995 Mar; 2(1):23-9. PubMed ID: 9137641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of age and HLA type on interferon-gamma (IFN-gamma) responses to a naturally occurring polymorphic epitope of Plasmodium falciparum liver stage antigen-1 (LSA-1).
    Bucci K; Kastens W; Hollingdale MR; Shankar A; Alpers MP; King CL; Kazura JW
    Clin Exp Immunol; 2000 Oct; 122(1):94-100. PubMed ID: 11012624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of antibody responses to the conserved Plasmodium falciparum merozoite surface protein 5 with protection against clinical malaria.
    Perraut R; Joos C; Sokhna C; Polson HE; Trape JF; Tall A; Marrama L; Mercereau-Puijalon O; Richard V; Longacre S
    PLoS One; 2014; 9(7):e101737. PubMed ID: 25047634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of immune responses against T- and B-cell epitopes from Plasmodium falciparum liver-stage antigen 1 in rodent malaria models and malaria-exposed human subjects in India.
    Joshi SK; Bharadwaj A; Chatterjee S; Chauhan VS
    Infect Immun; 2000 Jan; 68(1):141-50. PubMed ID: 10603380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope Mapping and Fine Specificity of Human T and B Cell Responses for Novel Candidate Blood-Stage Malaria Vaccine P27A.
    Geiger KM; Guignard D; Yang C; Bikorimana JP; Correia BE; Houard S; Mkindi C; Daubenberger CA; Spertini F; Corradin G; Audran R
    Front Immunol; 2020; 11():412. PubMed ID: 32210975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.
    Roussilhon C; Oeuvray C; Müller-Graf C; Tall A; Rogier C; Trape JF; Theisen M; Balde A; Pérignon JL; Druilhe P
    PLoS Med; 2007 Nov; 4(11):e320. PubMed ID: 18001147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo.
    Brahimi K; Badell E; Sauzet JP; BenMohamed L; Daubersies P; Guérin-Marchand C; Snounou G; Druilhe P
    Infect Immun; 2001 Jun; 69(6):3845-52. PubMed ID: 11349050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple antigen peptide vaccines against Plasmodium falciparum malaria.
    Mahajan B; Berzofsky JA; Boykins RA; Majam V; Zheng H; Chattopadhyay R; de la Vega P; Moch JK; Haynes JD; Belyakov IM; Nakhasi HL; Kumar S
    Infect Immun; 2010 Nov; 78(11):4613-24. PubMed ID: 20823210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic Antigens Derived from
    Pratt-Riccio LR; De Souza Perce-Da-Silva D; Da Costa Lima-Junior J; Pratt Riccio EK; Ribeiro-Alves M; Santos F; Arruda M; Camus D; Druilhe P; Oliveira-Ferreira J; Daniel-Ribeiro CT; Banic DM
    Am J Trop Med Hyg; 2017 Nov; 97(5):1581-1592. PubMed ID: 29016339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research note: HLA degenerate T-cell epitopes from Plasmodium falciparum liver stage-specific antigen 1 (LSA-1) are highly conserved in isolates from geographically distinct areas.
    Ravichandran M; Doolan DL; Cox-Singh J; Hoffman SL; Singh B
    Parasite Immunol; 2000 Sep; 22(9):469-73. PubMed ID: 10972854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of anti-Plasmodium IgG profiles among Fulani nomadic pastoralists in northern Senegal to assess malaria exposure.
    Seck MC; Thwing J; Badiane AS; Rogier E; Fall FB; Ndiaye PI; Diongue K; Mbow M; Ndiaye M; Diallo MA; Gomis JF; Mbaye A; Ndiaye T; Gaye A; Sy M; Déme AB; Ndiaye YD; Ndiaye D
    Malar J; 2020 Jan; 19(1):15. PubMed ID: 31931834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.